¶ circadian [1] Rhythm Disruption in Neurodegeneration
¶ Introduction
Circadian Rhythm Disruption In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ Overview
Circadian rhythms are endogenous ~24-hour biological oscillations that orchestrate nearly every physiological process, including the sleep [2]-wake cycle, hormone secretion, body temperature regulation, immune function, and metabolic homeostasis. In [neurodegenerative ], circadian rhythm disruption (CRD) is increasingly recognized not merely as a symptom but as a pathogenic mechanism that may precede clinical diagnosis by years and actively accelerate disease progression ([Musiek & Holtzman, 2016)]](https://https
/pubmed.ncbi.nlm.nih.gov/27618652/)) (Association et al., 2019).
The master circadian pacemaker resides in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus, which synchronizes peripheral oscillators throughout the brain and body to the external light-dark cycle. In [Alzheimer [4]'s disease (AD)], [Parkinson's Disease (PD)[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Huntington's Disease (HD)[/diseases/[huntingtons[/diseases/[huntingtons[/diseases/[huntingtons--TEMP--/diseases)--FIX--, and other neurodegenerative conditions, SCN degeneration, disrupted clock gene expression, melatonin deficiency, and fragmented sleep-wake patterns form a bidirectional vicious cycle: neurodegeneration damages the circadian system, and circadian dysfunction in turn accelerates neurodegeneration through impaired protein clearance, heightened neuroinflammation, oxidative stress, and disrupted [synaptic plasticity[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- ([Leng et al., 2019)(https://https/pubmed.ncbi.nlm.nih.gov/30737275/)) (Mechanisms et al., 2016).
Recent epidemiological data demonstrate that individuals with weaker and more irregular circadian rhythms have significantly increased dementia risk, reinforcing the clinical importance of circadian health as a modifiable factor in neurodegeneration (Molecular et al., 2015).
¶ Circadian Rhythm Pathway
¶ The Molecular Clock
¶ Core Clock Machinery
The mammalian circadian clock operates through interlocking transcriptional-translational feedback loops (TTFLs) (Circadian et al., 2013):
Core loop:
- CLOCK:BMAL1 heterodimer binds E-box elements (CACGTG) in promoter regions, activating transcription of Period (PER1/2/3) and Cryptochrome (CRY1/2) genes
- PER:CRY complexes accumulate in the cytoplasm, translocate to the nucleus, and inhibit CLOCK:BMAL1 activity, thereby repressing their own transcription
- The cycle resets as PER and CRY are degraded by casein kinase 1δ/ε (CK1δ/ε)-mediated phosphorylation and subsequent proteasomal degradation
Stabilizing loop:
- RORα/β/γ activate BMAL1 transcription
- REV-ERBα/β repress BMAL1 transcription
- This auxiliary loop provides stability and robustness to the core oscillator
¶ Clock-Controlled Outputs
The molecular clock regulates thousands of genes (clock-controlled genes, CCGs), including those involved in:
- autophagy and [proteostasis] — clearance of misfolded proteins is circadian-regulated
- [Mitochondrial] biogenesis and oxidative stress defense
- [Neuroinflammatory] responses — [microglial/long-term potentiation ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--
- [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- ([BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- permeability
- [Glymphatic system[/entities/[glymphatic-system[/entities/[glymphatic-system[/entities/[glymphatic-system--TEMP--/entities)--FIX-- clearance — peak activity during sleep
¶ Circadian Disruption in Alzheimer's Disease
¶ SCN Degeneration
The SCN undergoes significant neuronal loss in AD, with studies reporting 30-50% reduction in vasopressin-immunoreactive [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the SCN of AD patients compared to age-matched controls (Swaab et al., 1985). This degeneration leads to:
- Reduced amplitude of circadian outputs (temperature, cortisol, melatonin rhythms)
- Phase shifts (typically phase-advanced or phase-delayed)
- Fragmented rest-activity patterns
¶ Aβ-Induced Clock Disruption
[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- directly disrupts the molecular clock through multiple mechanisms (Regulation et al., 2018):
- BMAL1 degradation: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- induces post-translational degradation of BMAL1 and its transcriptional co-activator CBP (CREB-binding protein), reducing PER2 expression and disrupting the core feedback loop (Song et al., 2015)
- Epigenetic changes: Early AD stages show aberrant [DNA methylation[/entities/[dna-methylation[/entities/[dna-methylation[/entities/[dna-methylation--TEMP--/entities)--FIX-- patterns at the BMAL1 promoter, altering clock gene expression (Cronin et al., 2017) (Circadian et al., 2017)
- neuroinflammation: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---activated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--
- Sleep deprivation increases [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--: Even one night of sleep deprivation increases CSF [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- levels by ~30% and accelerates [amyloid plaque] deposition in mouse models (Shokri-Kojori et al., 2018)
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- disrupts sleep: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers impair slow-wave sleep and circadian regulation, creating a feedforward cycle
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- propagation: Sleep disruption also promotes tau] pathology] spreading, with tau levels in interstitial fluid showing circadian oscillation that is enhanced by wakefulness
¶ Tau Pathology and the SCN
Tau accumulation directly impacts the circadian system:
- Phosphorylated tau (p-tau immunoreactivity in the SCN region is accompanied by significant reduction in BMAL1 and PER2 oscillation amplitude
- Tau pathology in the hypothalamus disrupts the molecular feedback loop of the central clock
- In [Braak staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging--TEMP--/mechanisms)--FIX--, the hypothalamus (including SCN-adjacent areas) is affected by stages III-IV, coinciding with clinical emergence of sleep disturbances
¶ Melatonin Deficiency
Melatonin, the circadian hormone secreted by the pineal gland under SCN control, is significantly reduced in AD:
- CSF melatonin levels decline even in preclinical AD stages ([Braak I-II)
- Melatonin has both antioxidant and anti-amyloidogenic properties; its loss removes a protective buffer
- [Cholinergic] degeneration of the nucleus suprachiasmaticus pathway contributes to pineal melatonin suppression
- Sundowning syndrome (late-afternoon agitation) correlates with circadian phase disturbances and melatonin deficiency
¶ Circadian Disruption in Parkinson's Disease
¶ Sleep-Wake Disturbances in PD
Sleep disorders affect >80% of [PD] patients and include:
- [REM Sleep Behavior Disorder (RBD)[/diseases/[rem-sleep-behavior-disorder[/diseases/[rem-sleep-behavior-disorder[/diseases/[rem-sleep-behavior-disorder--TEMP--/diseases)--FIX--: Loss of REM atonia; a prodromal [synucleinopathy] that can precede motor symptoms by >10 years
- Excessive daytime sleepiness: Affects 30-50% of PD patients; linked to dopamine depletion and [orexin] system dysfunction
- Insomnia: Difficulty initiating and maintaining sleep; multifactorial
- Restless legs syndrome: Present in 15-20% of PD patients
¶ Dopaminergic Clock Regulation
dopamine and the circadian clock are intimately connected:
- Dopamine D2 receptors in the retina contribute to light entrainment
- The SCN receives dopaminergic input, and dopamine depletion alters circadian rhythm amplitude
- [Dopaminergic neuron] loss in the substantia nigra disrupts circadian modulation of motor function (explaining motor fluctuations in PD)
- clock genes [3] regulate dopamine synthesis enzymes (tyrosine hydroxylase, DOPA decarboxylase), creating circadian variation in dopamine levels
¶ alpha-synuclein and the Clock
[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- disrupts peripheral circadian oscillators
- BMAL1 expression is reduced in PD patient blood lymphocytes and post-mortem brain tissue
- Chronic circadian disruption in animal models accelerates [α-synuclein/proteins/alpha aggregation and [dopaminergic neuron] loss
¶ Circadian Disruption in Huntington's Disease
[HD] patients exhibit profound circadian disturbances that often precede motor symptoms:
- Disrupted rest-activity rhythms: Fragmented sleep-wake patterns observed in presymptomatic HD gene carriers
- Hypothalamic atrophy: SCN neuron loss occurs early in HD progression due to [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- aggregate toxicity
- Altered clock gene expression: R6/2 and Q175 HD mouse models show suppressed circadian gene oscillations in the SCN
- Melatonin dysregulation: Reduced melatonin secretion and delayed circadian phase
- Therapeutic potential: Restricted feeding schedules and bright light therapy improve circadian rhythms and delay symptom progression in HD mouse models (Pallier et al., 2007)
¶ Circadian Disruption in Other Neurodegenerative Diseases
¶ Frontotemporal Dementia (FTD)
[FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- patients show disrupted sleep-wake cycles, altered eating patterns (often shifted to nighttime), and reduced circadian rhythm amplitude. Hypothalamic [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- or tau pathology directly impacts SCN function.
¶ Amyotrophic Lateral Sclerosis (ALS)
[ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- patients experience progressive sleep disruption, partly due to respiratory muscle weakness but also due to intrinsic circadian alterations. BMAL1 expression is altered in ALS motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and [glial cells[/entities/[astrocytes[/entities/[astrocytes[/entities/[astrocytes--TEMP--/entities)--FIX--.
¶ Multiple System Atrophy (MSA)
[MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX-- is associated with severe autonomic circadian dysfunction, including loss of nocturnal blood pressure dipping and disrupted melatonin secretion, reflecting [α-synuclein/proteins/alpha pathology in autonomic regulatory centers.
¶ Mechanisms Linking Circadian Disruption to Neurodegeneration
¶ 1. Impaired Protein Clearance
The circadian clock directly regulates autophagy and [proteasomal] pathways:
- BMAL1 controls transcription of autophagy genes (Atg14, Ulk1, Becn1)
- [Glymphatic clearance] of [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau peaks during sleep
- Clock disruption reduces [autophagy-lysosomal] flux, promoting [protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX--
- REV-ERBα regulates microglial phagocytosis in a circadian manner
¶ 2. neuroinflammation
The immune system is under strong circadian control:
- Microglialinflammatory responses (cytokine release, phagocytosis oscillate with circadian rhythms
- BMAL1 deletion in [microglia/astrocytes] reactivity follows circadian patterns; disruption impairs their neuroprotective functions
¶ 3. Oxidative Stress
- Circadian clock genes regulate antioxidant defense enzymes (superoxide dismutase, catalase, glutathione peroxidase)
- BMAL1 knockout mice show accelerated aging and increased [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production
- [Mitochondrial] biogenesis and mitophagy are circadian-regulated; disruption leads to accumulation of dysfunctional mitochondria
- NAD+ levels oscillate with circadian rhythms; disruption depletes NAD+ and impairs sirtuin-mediated neuroprotection
¶ 4. Synaptic and Cognitive Dysfunction
- [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- and memory consolidation are circadian-regulated, peaking during specific circadian phases
- Sleep-dependent memory consolidation requires coordinated hippocampal sharp-wave ripples and neocortical slow oscillations
- Circadian disruption impairs hippocampal neurogenesis ([neurogenesis)
- BDNF expression follows circadian rhythms; disruption reduces neurotrophic support
¶ 5. Metabolic Dysfunction
- Circadian disruption promotes [insulin resistance] and metabolic dysfunction
- Clock-regulated glucose metabolism impairment worsens [brain insulin signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling--TEMP--/entities)--FIX--
- [Lipid metabolism] and [brain cholesterol] homeostasis are circadian-regulated
- Shift work and chronic jet lag are associated with increased dementia risk
¶ 6. Blood-Brain Barrier Integrity
- [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- permeability follows circadian rhythms, with tighter junctions during the active phase
- Circadian disruption increases [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- leakage, allowing peripheral inflammatory mediators to enter the brain ([BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- breakdown)
- [Pericyte] function and endothelial clock gene expression are disrupted in neurodegeneration
¶ Epidemiological Evidence
Several large-scale studies have linked circadian disruption to dementia risk:
- UK Biobank study: Actigraphy data from >90,000 participants showed that reduced circadian amplitude and increased fragmentation were associated with 40-50% increased risk of dementia over 7 years (Tranah et al., 2011)
- Nurses' Health Study: Rotating night shift work for ≥6 years was associated with accelerated cognitive decline and increased AD risk
- Rush Memory and Aging Project: Disrupted rest-activity circadian rhythms predicted incident AD and rate of cognitive decline (Lim et al., 2012)
- Neurology 2025 study: People with weaker and more irregular circadian rhythms had significantly higher dementia incidence, even after adjusting for known risk factors
- Lancet Commission on Dementia (2024): Sleep disturbances included among [modifiable risk factors[/mechanisms/[modifiable-risk-factors[/mechanisms/[modifiable-risk-factors[/mechanisms/[modifiable-risk-factors--TEMP--/mechanisms)--FIX-- for dementia
These findings suggest that circadian health is a potentially modifiable risk factor for neurodegeneration, distinct from but related to sleep quality.
¶ Therapeutic Approaches
¶ Light Therapy
Bright light therapy (BLT) is the most studied circadian intervention:
- Morning bright light (≥2,500 lux for 30-120 minutes): Improves circadian rhythm amplitude, reduces sundowning, and improves sleep in AD patients
- Blue-enriched light: More effective at suppressing melatonin and entraining SCN
- Dynamic lighting systems: Institutional settings with automated light cycling show cognitive and behavioral benefits in dementia care
¶ Melatonin and Melatonin Receptor Agonists
- Exogenous melatonin: Low-dose (0.5-3 mg) at bedtime improves sleep latency and circadian rhythm regularity in mild-moderate AD; evidence mixed for advanced dementia
- Ramelteon: MT1/MT2 melatonin receptor agonist; improves sleep initiation
- Tasimelteon: Dual MT1/MT2 agonist approved for non-24-hour sleep-wake disorder
- Suvorexant/Lemborexant: Orexin receptor antagonists improving sleep in AD patients (SUNRISE-AD trial)
¶ Chronotherapy
- Time-restricted feeding: Aligning food intake with circadian active phase strengthens peripheral oscillator synchronization
- Scheduled physical activity: Regular daytime exercise improves circadian rhythmicity and sleep quality
- Social rhythm therapy: Structured daily routines reinforcing environmental time cues (zeitgebers)
¶ Pharmacological Clock Modulators
Emerging therapeutic strategies targeting the molecular clock:
- REV-ERBα agonists: SR9009 and SR9011 enhance circadian amplitude and reduce neuroinflammation in mouse models
- CK1δ/ε inhibitors: Modulate PER protein degradation rate, adjusting circadian period
- Nobiletin: A natural flavonoid that enhances RORα/γ activity, strengthening circadian oscillation; shows neuroprotective effects in AD mouse models (Nohara et al., 2019)
- [GLP-1 receptor agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists--TEMP--/treatments)--FIX--: Emerging evidence that liraglutide restores disrupted circadian rhythms in neurodegeneration models
¶ Targeting the Glymphatic System
- Sleep optimization: Improving sleep quality to enhance glymphatic [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau clearance
- Body position: Lateral (side) sleeping position enhances glymphatic transport
- AQP4 modulation: Targeting aquaporin-4 water channels on astrocytic endfeet to enhance glymphatic flow
- Reducing [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- dysfunction: Protecting neurovascular unit integrity to maintain glymphatic function
¶ Experimental Models
¶ Genetic Models
- BMAL1 knockout mice: Global or tissue-specific BMAL1 deletion → accelerated aging, neuroinflammation, synaptic loss, and cognitive decline (Musiek et al., 2013)
- ClockΔ19 mice: Dominant-negative CLOCK mutation → disrupted circadian behavior and metabolic dysfunction
- PER2::Luc reporter mice: Crossed with AD/PD models to monitor circadian oscillation in real time
- SCN lesion models: Electrolytic or chemical SCN ablation → abolishes circadian rhythms, accelerates amyloid deposition
¶ Environmental Models
- Chronic jet lag: Repeated 6-hour phase shifts → accelerates [Aβ[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities//entities/Amyloid-Beta plaque deposition, cognitive decline, and neuroinflammation in AD mouse models
- Constant light/darkness: Disrupts SCN function, accelerates age-related cognitive decline
- Shift work simulation: Alternating light-dark schedules → metabolic dysfunction, increased neuroinflammation
¶ Circadian Biomarkers
Measuring circadian disruption in clinical settings:
| Biomarker | Method | Clinical Utility |
|---|---|---|
| Actigraphy | Wrist-worn accelerometer (7+ days) | Rest-activity rhythm amplitude, fragmentation, regularity (interdaily stability, intradaily variability) |
| Melatonin rhythm | Dim-light melatonin onset (DLMO) in saliva/plasma | Circadian phase marker; gold standard for phase assessment |
| Core body temperature | Continuous monitoring | Circadian amplitude and phase; dampened in AD |
| Cortisol rhythm | Serial saliva samples | Flattened cortisol rhythm in AD and PD |
| Clock gene expression | Blood mononuclear cell mRNA | BMAL1, PER, CRY expression patterns; research use |
| Sleep polysomnography | Overnight PSG | Sleep architecture, RBD screening |
¶ Current Research Frontiers
- Circadian-based clinical trials: Designing trials that account for circadian timing of drug administration (chronopharmacology) to optimize therapeutic efficacy
- Digital circadian biomarkers: Smartphone and wearable-based continuous circadian rhythm monitoring for early detection of neurodegeneration risk
- Cell-type-specific circadian disruption: Understanding how clock dysfunction differs across [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- composition follows circadian patterns; disruption may influence neurodegeneration via gut-brain signaling
- Precision chronotherapy: Personalized circadian interventions based on individual chronotype and disease stage
- Circadian gene therapy: Restoring BMAL1 expression in the SCN or targeted brain regions using viral vectors
¶ See Also
- [Mechanisms of Neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
¶ Background
The study of Circadian Rhythm Disruption In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
- PubMed - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
¶ References
- [Musiek, E.S. & Holtzman, D.M. (2016]. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science, 354(6315), 1004-1008. PubMed)
- [Leng, Y., Musiek, E.S., Hu, K., Cappuccio, F.P. & Yaffe, K. (2019]. Association between circadian rhythms and neurodegenerative diseases. The Lancet Neurology, 18(3), 307-318. PubMed)
- [Swaab, D.F., Fliers, E. & Partiman, T.S. (1985]. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Research, 342(1), 37-44. PubMed)
- [Song, H., Moon, M., Choe, H.K., et al. (2015]. [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer's Disease. Molecular Neurodegeneration, 10, 13. PubMed)
- [Cronin, P., McCarthy, M.J., Lim, A.S.P., et al. (2017]. Circadian alterations during early stages of Alzheimer's Disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimer's & Dementia, 13(6), 689-700. PubMed)
- [Xie, L., Kang, H., Xu, Q., et al. (2013]. Sleep drives metabolite clearance from the adult brain. Science, 342(6156), 373-377. PubMed)
- [Shokri-Kojori, E., Wang, G.J., Wiers, C.E., et al. (2018]. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proceedings of the National Academy of Sciences, 115(17), 4483-4488. PubMed)
- [Pallier, P.N., Maywood, E.S., Zheng, Z., et al. (2007]. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's Disease. Journal of Neuroscience, 27(29), 7869-7878. PubMed)
- [Lim, A.S.P., Kowgier, M., Yu, L., Buchman, A.S. & Bennett, D.A. (2012]. Sleep fragmentation and the risk of incident Alzheimer's Disease and cognitive decline in older persons. Sleep, 36(7), 1027-1032. PubMed)
- [Tranah, G.J., Blackwell, T., Stone, K.L., et al. (2011]. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Annals of Neurology, 70(5), 722-732. PubMed)
- [Musiek, E.S., Lim, M.M., Yang, G., et al. (2013]. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. Journal of Clinical Investigation, 123(12), 5389-5400. PubMed)
- [Nohara, K., Mallampalli, V., Nemkov, T., et al. (2019]. Nobiletin fortifies mitochondrial respiration in skeletal muscle to promote healthy aging against metabolic challenge. Nature Communications, 10(1), 3923. PubMed)
- [Videnovic, A., Lazar, A.S., Barker, R.A. & Overeem, S. (2014]. "The clocks that time us" — circadian rhythms in neurodegenerative disorders. Nature Reviews Neurology, 10(12), 683-693. PubMed)
- [Kress, G.J., Liao, F., Dimitry, J., et al. (2018]. Regulation of amyloid-β dynamics and pathology by the circadian clock. Journal of Experimental Medicine, 215(4), 1059-1068. PubMed)
- [Holth, J.K., Fritschi, S.K., Wang, C., et al. (2019]. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science, 363(6429), 880-884. PubMed)
¶ Confidence Assessment
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 49%